Drug Overview
Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment of schizophrenia. Eli Lilly subsequently pursued development in bipolar disorder and received the first approval for Zyprexa as a monotherapy in the treatment of manic and mixed episodes in 2000.
Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment of schizophrenia. Eli Lilly subsequently pursued development in bipolar disorder and received the first approval for Zyprexa as a monotherapy in the treatment of manic and mixed episodes in 2000.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Zyprexa: Bipolar disorder
Zyprexa: Schizophrenia
List of Figures
Figure 1: Zyprexa for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Zyprexa in bipolar disorder
Figure 3: Drug assessment summary for Zyprexa in bipolar disorder
Figure 4: Zyprexa for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of Zyprexa for schizophrenia
Figure 6: Drug assessment summary of Zyprexa for schizophrenia
Figure 7: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Zyprexa bipolar disorder indication approvals
Table 2: Zyprexa drug profile
Table 3: Overview of key pivotal trial data for Zyprexa in bipolar disorder
Table 4: Adverse reactions reported in =5% of patients in six-week clinical trials of Zyprexa as an adjunct to lithium or valproate in adult bipolar disorder (manic/mixed episodes)
Table 5: Key side effects reported in clinical trials of Zyprexa in bipolar disorder
Table 6: Zyprexa drug profile
Table 7: Zyprexa pivotal trial data in schizophrenia
Table 8: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017-26
